Dr. Rugo Discusses Immunotherapy in TNBC

Hope Rugo, MD
Published: Tuesday, Nov 14, 2017



Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).

Immunotherapy agents need to be started earlier in TNBC, says Rugo, as that is where the best response is seen.

As cancers progress, mutational load increases neoantigens. If a tumor has an increased mutational load, the tumor can progress and develop more resistance—creating more mechanisms of avoiding an immune response, which Rugo says are beyond a checkpoint inhibitor.
 
SELECTED
LANGUAGE


Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).

Immunotherapy agents need to be started earlier in TNBC, says Rugo, as that is where the best response is seen.

As cancers progress, mutational load increases neoantigens. If a tumor has an increased mutational load, the tumor can progress and develop more resistance—creating more mechanisms of avoiding an immune response, which Rugo says are beyond a checkpoint inhibitor.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x